{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:36:18Z","timestamp":1777404978296,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010434","name":"Caixabank SA","doi-asserted-by":"publisher","award":["HR21-00931"],"award-info":[{"award-number":["HR21-00931"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CB18\/05\/00040"],"award-info":[{"award-number":["CB18\/05\/00040"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005765","name":"University of Lisbon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","award":["PID2021-128906OB-100"],"award-info":[{"award-number":["PID2021-128906OB-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neuropharm.2025.110804","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:41:44Z","timestamp":1765471304000},"page":"110804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Assessment of the therapeutic effect of IGS2.7, a CK1\u03b4 protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy"],"prefix":"10.1016","volume":"285","author":[{"given":"Marta","family":"Gomez-Almeria","sequence":"first","affiliation":[]},{"given":"Loreto","family":"Martinez-Gonzalez","sequence":"additional","affiliation":[]},{"given":"Ana Teresa","family":"Matos","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Rodriguez-Cueto","sequence":"additional","affiliation":[]},{"given":"Ana Rita","family":"Vaz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2570-2577","authenticated-orcid":false,"given":"Raquel","family":"Mart\u00edn-Baquero","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"P\u00e9rez de la Lastra","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7656-0262","authenticated-orcid":false,"given":"Rafael","family":"Infantes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-0604","authenticated-orcid":false,"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[]},{"given":"Valle","family":"Palomo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-6081","authenticated-orcid":false,"given":"Carmen","family":"Gil","sequence":"additional","affiliation":[]},{"given":"Dora","family":"Brites","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Martinez","sequence":"additional","affiliation":[]},{"given":"Eva","family":"de Lago","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110804_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-016-0102-7","article-title":"Targeting TDP-43 phosphorylation by Casein Kinase-1\u03b4 inhibitors: a novel strategy for the treatment of frontotemporal dementia","volume":"11","author":"Alquezar","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110804_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.neuropharm.2025.110804_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102085","article-title":"TDP-43 as a therapeutic target in neurodegenerative diseases: focusing on motor neuron disease and frontotemporal dementia","volume":"92","author":"Babazadeh","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2025.110804_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.634355","article-title":"Recovery of depleted miR-146a in ALS cortical astrocytes reverts cell aberrancies and prevents paracrine pathogenicity on Microglia and motor neurons","volume":"9","author":"Barbosa","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib5","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/biomedicines10092120","article-title":"Intrathecal injection of the secretome from ALS motor neurons regulated for miR-124 expression prevents disease outcomes in SOD1-G93A mice","volume":"10","author":"Barbosa","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuropharm.2025.110804_bib6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2025.110804_bib7","first-page":"293","article-title":"World Federation of neurology research group on motor neuron diseases, El escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, amyotroph. Lateral scler. Mot","volume":"1","author":"Brooks","year":"2000","journal-title":"Neuron Disord. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis."},{"key":"10.1016\/j.neuropharm.2025.110804_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/biomedicines10020385","article-title":"TDP-43 pathology and prionic behavior in human cellular models of Alzheimer's disease patients","volume":"10","author":"Cuevas","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuropharm.2025.110804_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106430","article-title":"Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosis","volume":"192","author":"Cuevas","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110804_bib10","first-page":"4207","article-title":"Downregulated glia interplay and increased miRNA-155 as promising markers to track ALS at an early stage","volume":"55","author":"Cunha","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","article-title":"Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders","volume":"10","author":"Espejo-Porras","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib12","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bph.14216","article-title":"Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis","volume":"176","author":"Espejo-Porras","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110804_bib49","doi-asserted-by":"crossref","first-page":"118288","DOI":"10.1016\/j.biopha.2025.118288","article-title":"Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis","volume":"189","author":"Garc\u00eda-Toscano","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110804_bib16","article-title":"MicroRNA-146a negatively regulates inflammation via the IRAK1\/TRAF6\/NF-\u03baB signaling pathway in dry eye","volume":"13","author":"Han","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110804_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1326-9-24","article-title":"Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice","volume":"9","author":"Herdewyn","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110804_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1326-9-24","article-title":"Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice","volume":"9","author":"Herdewyn","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110804_bib19","first-page":"220","article-title":"Altered Ca2+ homeostasis in lymphoblasts from patients with late-onset alzheimer disease","volume":"11","author":"Ibarreta","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2025.110804_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2016.00295","article-title":"Riluzole but not melatonin ameliorates acute motor neuron degeneration and moderately inhibits SOD1-Mediated excitotoxicity induced disrupted mitochondrial Ca2+ signaling in amyotrophic lateral sclerosis","volume":"10","author":"Jaiswal","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111001","article-title":"Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy","volume":"39","author":"Krus","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2025.110804_bib22","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1111\/jcmm.15490","article-title":"MicroRNA-183-5p is stress-inducible and protects neurons against cell death in amyotrophic lateral sclerosis","volume":"24","author":"Li","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110804_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101803","article-title":"miR-129-5p: a key factor and therapeutic target in amyotrophic lateral sclerosis","volume":"190","author":"Loffreda","year":"2020","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49424-3","article-title":"The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe","volume":"13","author":"Ludolph","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110804_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12868-024-00846-3","article-title":"Tmem119 expression is downregulated in a subset of brain metastasis-associated microglia","volume":"25","author":"Ma","year":"2024","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib26","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1038\/s41598-020-61265-y","article-title":"Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1\u03b4 kinase inhibitor treatment","volume":"10","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110804_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00401-012-1043-z","article-title":"Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion","volume":"125","author":"Mitchell","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fncel.2020.00117","article-title":"Cytoplasmic TDP43 binds microRNAs: new disease targets in amyotrophic lateral sclerosis","volume":"14","author":"Paez-Colasante","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00117","article-title":"Cytoplasmic TDP43 binds microRNAs: new disease targets in amyotrophic lateral sclerosis","volume":"14","author":"Paez-Colasante","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib30","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/bph.15221","article-title":"Protein kinase inhibitors for amyotrophic lateral sclerosis therapy","volume":"178","author":"Palomo","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib31","article-title":"Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms","volume":"11","author":"Pansarasa","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2025.110804_bib32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jns.2017.07.008","article-title":"Micro-RNAs in ALS muscle: differences in gender, age at onset and disease duration","volume":"380","author":"Pegoraro","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib33","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1021\/acschemneuro.4c00328","article-title":"Proteome aggregation in cells derived from amyotrophic lateral sclerosis patients for personalized drug evaluation","volume":"15","author":"P\u00e9rez de la Lastra Aranda","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00273","article-title":"Exosomes from NSC-34 cells transfected with hSOD1-G93A are enriched in miR-124 and drive alterations in microglia phenotype","volume":"11","author":"Pinto","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib35","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1007\/s12035-018-1249-8","article-title":"Recapitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients","volume":"56","author":"Posa","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib36","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/pathogens10111459","article-title":"Insights into the SARS-CoV-2-Mediated alteration in the stress granule protein regulatory networks in humans","volume":"10","author":"Prasad","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.neuropharm.2025.110804_bib37","article-title":"Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis","volume":"31","author":"Rodr\u00edguez-Cueto","year":"2021","journal-title":"Brain Pathol. Zurich Switz"},{"key":"10.1016\/j.neuropharm.2025.110804_bib38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2217\/nmt-2020-0033","article-title":"Riluzole for the treatment of amyotrophic lateral sclerosis","volume":"10","author":"Saitoh","year":"2020","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.neuropharm.2025.110804_bib39","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/jm500065f","article-title":"Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis","volume":"57","author":"Salado","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110804_bib40","article-title":"Critical issues in the use of edaravone for the treatment of amyotrophic lateral sclerosis","author":"Seok","year":"2025","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2025.110804_bib41","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.14440\/jbm.2017.148","article-title":"Total proteome turbidity assay for tracking global protein aggregation in the natural cellular environment","volume":"4","author":"Shmueli","year":"2017","journal-title":"J. Biol. Method."},{"key":"10.1016\/j.neuropharm.2025.110804_bib42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/biology12081091","article-title":"Towards an understanding of microglia and border-associated macrophages","volume":"12","author":"Taketomi","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.neuropharm.2025.110804_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/jnc.15118","article-title":"Therapeutic potential of novel cell division cycle kinase 7 inhibitors on TDP-43-related pathogenesis such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)","volume":"156","author":"Vaca","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110804_bib44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s40478-019-0850-z","article-title":"Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment","volume":"7","author":"van Wageningen","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuropharm.2025.110804_bib45","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.3390\/ijms22116128","article-title":"Overexpression of miR-124 in motor neurons plays a key role in ALS pathological processes","volume":"22","author":"Vaz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110804_bib46","doi-asserted-by":"crossref","first-page":"18809","DOI":"10.1073\/pnas.0908767106","article-title":"TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration","volume":"106","author":"Wegorzewska","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2025.110804_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jnc.14229","article-title":"Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: altered expression of miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9","volume":"145","author":"Zhou","year":"2018","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110804_bib48","first-page":"3078","article-title":"MicroRNA-146a inhibits NF-\u03baB activation and pro-inflammatory cytokine production by regulating IRAK1 expression in THP-1 cells","volume":"18","author":"Zhou","year":"2019","journal-title":"Exp. Ther. Med."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500512X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500512X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:18:26Z","timestamp":1773893906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082500512X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"alternative-id":["S002839082500512X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110804","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the therapeutic effect of IGS2.7, a CK1\u03b4 protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110804"}}